Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cobicistat

FDA-approved product (tablet, oral), marketed as Cobicistat, Tybost.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cobicistat
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other therapeutic products
FDA pharmacologic class
Cytochrome P450 3A Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cobicistat in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cobicistat with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants

    NCT04208061 · start 2019-12-18

    Registered record
    Registry ID
    NCT04208061
    Conditions
    Healthy
    Interventions
    Dabigatran Etexilate; DRV/COBI; Ritonavir; Darunavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-12-18
    Completion
    2021-04-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDabigatran Etexilate; DRV/COBI; Ritonavir; Darunavir
    PhasePhase 1
    Registry statusCompleted

  • A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

    NCT04065399 · start 2019-11-05

    Registered record
    Registry ID
    NCT04065399
    Conditions
    Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Mixed Lineage Acute Leukemia; Mixed Phenotype Acute Leukemia; Acute Leukemia of Ambiguous Lineage
    Interventions
    revumenib; cobicistat
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2019-11-05
    Completion
    2027-12-15
    Enrolment
    447

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Mixed Lineage Acute Leukemia; Mixed Phenotype Acute Leukemia +1 more
    Interventionrevumenib; cobicistat
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

    NCT04006704 · start 2019-10-10

    Registered record
    Registry ID
    NCT04006704
    Conditions
    HIV-1
    Interventions
    D/C/F/TAF FDC placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-10-10
    Completion
    2020-03-06
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionD/C/F/TAF FDC placebo
    PhasePhase 1
    Registry statusCompleted

  • Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study

    NCT03842488 · start 2019-04

    Registered record
    Registry ID
    NCT03842488
    Conditions
    HIV Infections
    Interventions
    Experimental: RAL QD; Active comparator: DRV/cb
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-04
    Completion
    2021-03
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionExperimental: RAL QD; Active comparator: DRV/cb
    PhasePhase 4
    Registry statusUnknown

  • The Late Presenter Treatment Optimisation Study

    NCT03696160 · start 2019-03-05

    Registered record
    Registry ID
    NCT03696160
    Conditions
    HIV/AIDS
    Interventions
    Biktarvy; Symtuza
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-03-05
    Completion
    2024-06-17
    Enrolment
    447

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS
    InterventionBiktarvy; Symtuza
    PhasePhase 3
    Registry statusCompleted

  • A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression

    NCT03693508 · start 2018-04-13

    Registered record
    Registry ID
    NCT03693508
    Conditions
    HIV Infections; Severe Immunosuppression
    Interventions
    Genvoya®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-04-13
    Completion
    2020-05-28
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Severe Immunosuppression
    InterventionGenvoya®
    PhasePhase 4
    Registry statusCompleted

  • Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfection

    NCT03425994 · start 2018-02-06

    Registered record
    Registry ID
    NCT03425994
    Conditions
    Chronic Hepatitis B in HIV Patient; Kidney Injury; Bone Diseases
    Interventions
    Elvitegravir/Cobicistat/Emtricitabine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-02-06
    Completion
    2019-10-11
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B in HIV Patient; Kidney Injury; Bone Diseases
    InterventionElvitegravir/Cobicistat/Emtricitabine
    PhaseNot recorded
    Registry statusUnknown

  • ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

    NCT03480646 · start 2017-11-15

    Registered record
    Registry ID
    NCT03480646
    Conditions
    Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Interventions
    CPI-1205; Cobicistat; Enzalutamide; Abiraterone; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-11-15
    Completion
    2021-02-03
    Enrolment
    175

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration Resistant Prostate Cancer (mCRPC)
    InterventionCPI-1205; Cobicistat; Enzalutamide; Abiraterone +1 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

    NCT03256422 · start 2017-09-07

    Registered record
    Registry ID
    NCT03256422
    Conditions
    HIV Infections
    Interventions
    Treatment discontinuation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-07
    Completion
    2020-03-02
    Enrolment
    640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTreatment discontinuation
    PhasePhase 3
    Registry statusCompleted

  • Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection

    NCT03205696 · start 2017-08-01

    Registered record
    Registry ID
    NCT03205696
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Antiretrovirals
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-08-01
    Completion
    2023-11-30
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionAntiretrovirals
    PhaseNot recorded
    Registry statusCompleted

  • Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

    NCT02998320 · start 2017-03-10

    Registered record
    Registry ID
    NCT02998320
    Conditions
    HIV Risk
    Interventions
    Genvoya
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-03-10
    Completion
    2018-09-30
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Risk
    InterventionGenvoya
    PhasePhase 3
    Registry statusCompleted

  • RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection

    NCT04064632 · start 2017-02-01

    Registered record
    Registry ID
    NCT04064632
    Conditions
    HIV Infection
    Interventions
    Rilpivirine + darunavir/cobicistat
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-02-01
    Completion
    2019-11-30
    Enrolment
    1,609

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionRilpivirine + darunavir/cobicistat
    PhasePhase 4
    Registry statusUnknown

  • Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice

    NCT03042390 · start 2016-12-23

    Registered record
    Registry ID
    NCT03042390
    Conditions
    HIV Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-12-23
    Completion
    2017-05-09
    Enrolment
    762

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment

    NCT02735863 · start 2016-05

    Registered record
    Registry ID
    NCT02735863
    Conditions
    HIV Infection
    Interventions
    ABX464; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-05
    Completion
    2018-01-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionABX464; Placebo
    PhasePhase 2
    Registry statusCompleted

  • HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection

    NCT02660905 · start 2016-04

    Registered record
    Registry ID
    NCT02660905
    Conditions
    Human Immunodeficiency Virus; Hepatitis C, Chronic
    Interventions
    E/C/F/TAF; Ledipasvir-Sofosbuvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-04
    Completion
    2018-06
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus; Hepatitis C, Chronic
    InterventionE/C/F/TAF; Ledipasvir-Sofosbuvir
    PhasePhase 3
    Registry statusCompleted